AKTX — Akari Therapeutics Share News
0.000.00%
Last trade - 00:00Regains Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Akari Therapeutics Announces Establishment Of Boston U.S. Headquarters Office
Brief: Akari Therapeutics PLC Announces ADS Ratio Change
Brief: Akari Therapeutics Says Nomacopan Receives Orphan Drug Designation From European Commission
Brief: Akari Therapeutics Appoints Wendy Dicicco As Interim CFO
Akari Therapeutics PLC expected to post a loss of 6 cents a share - Earnings Preview
Brief: Akari Therapeutics Provides Updates On Development Of Nomacopan In Pediatric And Adult HSCT-TMA
Brief: Akari Therapeutics Provides Update On Development Of PAS-Nomacopan
Brief: Akari Therapeutics Receives Positive Opinion On Orphan Drug Designation From The European Medicines Agency For Nomacopan For Treatment In Hematopoietic Stem Cell Transplantation
Brief: Aspira Women's Health Names Torsten Hombeck As Chief Financial Officer
Brief: Akari Therapeutics Says On May 1, Torsten Hombeck, CFO, Delivered Notice Of Resignation
Brief: Akari Therapeutics Granted 180-Day Extension By Nasdaq To Meet Minimum Bid Price Requirement
Akari Therapeutics PLC expected to post a loss of 4 cents a share - Earnings Preview
Brief: Poland And U.K. Regulatory Authorities Approve Use Of New, Higher-Yielding Manufacturing Process For Nomacopan In Pivotal Clinical Study
Brief: Akari Therapeutics PLC Says Does Not Hold Any Deposits Or Securities At SVB, Has No Accounts At SVB
Brief: Akari Therapeutics Announces Presentation Of Case Study From Phase 3 Part A Clinical Trial Of Nomacopan
Brief: Akari Therapeutics Announces Pre-Clinical Development Progress On Long-Acting Pas-Nomacopan
Brief: Akari Therapeutics Announces Acceleration Of Phase 3 Clinical Trial Of Nomacopan
Brief: Akari Therapeutics Moving Forward Into Design And Planning For Part B Of Phase 3 Clinical Trial Of Nomacopan